Korean Circ J.  2007 Nov;37(11):530-537. 10.4070/kcj.2007.37.11.530.

Comparison of the Predictors of Coronary Restenosis after Drug-Eluting Stent Implantation in Diabetic and Nondiabetic Patients

• Hong SJ
• Kim MH
• Ahn TH
• Shim WJ
• Park SM
• Choi JI
• Joo HJ
• Shin SY
• Lim SY
• Lim DS

• KMID: 1909613
• DOI: http://doi.org/10.4070/kcj.2007.37.11.530

Abstract

BACKGROUND AND OBJECTIVES: Coronary restenosis after drug-eluting stent (DES) implantation occurs more frequently in diabetic patients than in nondiabetic patients. We compared the parameters influencing the like-lihood of restenosis after DES implantation in diabetic and nondiabetic patients.
SUBJECTS AND METHODS
Patients who underwent DES implantation (619 patients with 917 lesions, 211 diabetics and 408 nondiabetics), followed by 8 months coronary angiogram, were retrospectively identified using the percutaneous coronary intervention database and included in the present study [AH1]. Predictors of restenosis were identified by multivariate logistic regression analyses.
RESULTS
The baseline characteristics of the patients, such as sex, body mass index, hypertension, hyperlipidemia, and smoking status, were similar between the diabetic and nondiabetic patients. Restenosis (>50% of the diameter stenosis) occurred in 32 of 408 (7.8%) nondiabetic patients and in 32 (15.2%) of 211 diabetic patients (p<0.001). The use of a paclitaxel-eluting stent (PES), a higher level of C-reactive protein (CRP), longer stent length, smaller reference diameter (RD) before DES implantation, smaller RD and minimal lumen diameter after DES implantation were common predictors of restenosis in both the diabetic and nondiabetic patients after multivariate analyses. Current smoking status [odds ratio (OR)=3.213, 95% confidence interval (CI) 1.458 to 7.080 p=0.004] and right coronary lesions (OR=2.444, 95% CI 1.048 to 5.703, p=0.039) were predictors of restenosis in the diabetic patients, while higher body mass index (OR=1.322, 95% CI 1.054 to 1.659, p=0.016) and A-type lesions (OR=0.108, 95% CI 0.022 to 0.530, p=0.006) were predictors of restenosis in the nondiabetic patients.
CONCLUSION
The use of PESs and higher levels of CRP were associated with restenosis regardless of the presence of diabetes. Moreover, small baseline and post-PCI reference diameter and longer stent length remained significant angiographic predictors of restenosis in both diabetic and nondiabetic patients, even in the era of DES implantation.

Keyword

Diabetes mellitus; Drug-eluting stent; Coronary restenosis

MeSH Terms

Body Mass Index
C-Reactive Protein
Coronary Restenosis*
Diabetes Mellitus
Drug-Eluting Stents*
Humans
Hyperlipidemias
Hypertension
Logistic Models
Multivariate Analysis
Percutaneous Coronary Intervention
Retrospective Studies
Smoke
Smoking
Stents
C-Reactive Protein
Smoke

Reference

1. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era. Circulation. 2004. 109:476–480.

2. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998. 32:1866–1873.

3. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med. 1993. 118:344–349.

4. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004. 350:221–231.

5. Grube E, Silber S, Hauptmann KE, et al. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003. 107:38–42.

6. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003. 349:1315–1323.

7. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004. 109:634–640.

8. Gaspardone A, Versaci F, Tomai F, et al. C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol. 2006. 97:1311–1316.

9. Kuchulakanti PK, Torguson R, Canos D, et al. Impact of treatment of coronary artery disease with sirolimus-eluting stents on outcomes of diabetic and nondiabetic patients. Am J Cardiol. 2005. 96:1100–1106.

10. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005. 45:1172–1179.

11. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients. Circulation. 2004. 109:2273–2278.

12. Lim DS. Coronary restenosis after drug-eluting stent implantation in diabetic patients. Korean Circ J. 2006. 36:1–7.

13. Leon MB, Bakhai A. Drug-eluting stents and glycoprotein Iib/ IIIa inhibitors: combination therapy for the future. Am Heart J. 2003. 146:S13–S17.

14. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart. 2003. 89:218–224.

15. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet. 2003. 361:247–249.

16. Lee CW, Park SJ. Predictive factors for restenosis after drug-eluting stent implantation. Korean Circ J. 2007. 37:97–102.

17. Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol. 2001. 38:645–652.

18. Kim BK, Oh SJ, Jeon DW, et al. Clinical outcomes following sirolimus-eluting stent implantation in patients with end-stage renal disease. Korean Circ J. 2006. 36:424–430.

19. West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation. 2004. 109:867–873.

20. Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J. 2003. 145:1013–1021.